Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Carnaxide – page 2

39 clinical trials in Carnaxide, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Carnaxide at a glance
39
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

39 trials in Carnaxide

Open in trial search

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Aortic valve stenosis

Not yet recruiting

A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Kardigan Inc.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Focal segmental glomerulosclerosis

Not yet recruiting

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Heart disease congenital

Not yet recruiting

Safety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Chiesi Farmaceutici S.p.A.

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Hypertriglyceridaemia+1

Not recruiting

Study of Olezarsen (ISIS 678354) for Patients with High Triglycerides and Heart Disease or Severe High Triglycerides

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Carnaxide

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on atherosclerotic cardiovascular disease and heart conditions, including trials evaluating new treatments for hypertrophic cardiomyopathy and pediatric heart failure.

  • Cardiovascular Disease Prevention
  • Heart Failure Management
  • Atrial Fibrillation Treatment

Research aims to reduce major cardiovascular events and improve patient outcomes through novel therapeutic approaches.

02 Nephrology Studies

Comprehensive research into kidney disorders, with a focus on IgA Nephropathy and innovative treatments for chronic kidney disease. Multiple trials are investigating new therapeutic options for patients with various forms of kidney dysfunction.

  • Kidney Transplantation
  • Lupus Nephritis
  • Glomerular Diseases

Studies aim to improve kidney function and reduce disease progression in patients with various renal conditions.

03 Metabolic Disorders

Advanced research targeting hypertriglyceridemia and related metabolic conditions. Studies focus on novel treatments for patients with severe metabolic disorders and associated cardiovascular risks.

  • Lipid Management
  • Secondary Hyperparathyroidism
  • Metabolic Disease Complications

Investigations concentrate on developing targeted therapies to address complex metabolic disorders and their complications.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.